Second-generation antipsychotics: Discrepancies between licensed indications, evidence base and actual use [2]

Psychopharmacology

Volumn 169, Issue 2, 2003, Pages 207-210

  Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZOTEPINE;

ACUTE DISEASE; CHRONIC DISEASE; DRUG INDICATION; DRUG USE; EUROPE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; UNITED KINGDOM; UNITED STATES;

ANTIPSYCHOTIC AGENTS; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; LEGISLATION, PHARMACY; LICENSURE, PHARMACY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; UNITED STATES;

EID: 0141854164     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1496-9     Document Type: Letter

References (5)

1. Barbui C, Tansella M, Garattini S (2003) Varying and "atypical" indications for atypical antipsychotics. Psychopharmacology DOI 10.1007/s00213-003-1495-x
2. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371-1376
3. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, Lieberman JA, Lopez-Ibor JJ, van Raay B, Twomey E (2002) The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry 15[Suppl 1]:S1-S51
4. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, Lieberman JA, Lopez-Ibor JJ, van Raay B, Twomey E (2003) The usefulness and use of second-generation antipsychotic medications - an update. Curr Opin Psychiatry 16[Suppl 1]:S1-S44
5. Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker WW (2000) Off-label use of antipsychotic drugs. J Clin Psychopharmacol 20:695-698